MLICM
PTCT icon

Metropolitan Life Insurance Company (MetLife)’s PTC Therapeutics PTCT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,793
Closed -$110K – 1615
2024
Q1 		$110K Sell
3,793
-289
-7% -$8.1K ﹤0.01% 997
2023
Q4 		$113K Hold
4,082
– – 0.01% 1012
2023
Q3 		$91.5K Buy
4,082
+231
+6% +$8.59K ﹤0.01% 1072
2023
Q2 		$157K Buy
3,851
+82
+2% +$4.01K 0.01% 793
2023
Q1 		$183K Sell
3,769
-572
-13% -$26.1K 0.01% 709
2022
Q4 		$166K Buy
4,341
+101
+2% +$4.2K 0.01% 790
2022
Q3 		$213K Hold
4,240
– – 0.01% 654
2022
Q2 		$170K Sell
4,240
-278
-6% -$9.75K 0.01% 779
2022
Q1 		$169K Sell
4,518
-13,448
-75% -$518K 0.01% 906
2021
Q4 		$716K Sell
17,966
-1,171
-6% -$44.8K 0.01% 1190
2021
Q3 		$712K Buy
19,137
+3
+0% +$123 0.01% 1199
2021
Q2 		$809K Buy
19,134
+2,379
+14% +$102K 0.01% 1169
2021
Q1 		$793K Sell
16,755
-808
-5% -$48K 0.01% 1116
2020
Q4 		$1.07M Sell
17,563
-740
-4% -$43.6K 0.02% 831
2020
Q3 		$856K Sell
18,303
-270
-1% -$13.3K 0.01% 837
2020
Q2 		$942K Hold
18,573
– – 0.02% 773
2020
Q1 		$829K Buy
18,573
+210
+1% +$10.6K 0.02% 775
2019
Q4 		$882K Sell
18,363
-296
-2% -$12.6K 0.01% 967
2019
Q3 		$631K Buy
18,659
+1,653
+10% +$71.9K 0.01% 1144
2019
Q2 		$765K Buy
17,006
+496
+3% +$19.6K 0.01% 1050
2019
Q1 		$621K Buy
16,510
+1,327
+9% +$44.6K 0.01% 1160
2018
Q4 		$521K Buy
15,183
+414
+3% +$14.9K 0.01% 1171
2018
Q3 		$694K Hold
14,769
– – 0.01% 1147
2018
Q2 		$498K Buy
14,769
+1,753
+13% +$54.7K 0.01% 1314
2018
Q1 		$352K Hold
13,016
– – 0.01% 1499
2017
Q4 		$217K Sell
13,016
-14,377
-52% -$243K ﹤0.01% 1866
2017
Q3 		$548K Buy
27,393
+3,863
+16% +$75.6K ﹤0.01% 1633
2017
Q2 		$431K Hold
23,530
– – ﹤0.01% 1808
2017
Q1 		$232K Hold
23,530
– – ﹤0.01% 2172
2016
Q4 		$257K Buy
23,530
+3,493
+17% +$36.6K ﹤0.01% 2186
2016
Q3 		$281K Sell
20,037
-3,666
-15% -$29.8K ﹤0.01% 2109
2016
Q2 		$166K Hold
23,703
– – ﹤0.01% 2450
2016
Q1 		$153K Hold
23,703
– – ﹤0.01% 2331
2015
Q4 		$768K Hold
23,703
– – 0.01% 1329
2015
Q3 		$633K Hold
23,703
– – ﹤0.01% 1478
2015
Q2 		$1.14M Buy
23,703
+4,799
+25% +$280K 0.01% 1202
2015
Q1 		$1.15M Sell
18,904
-102,746
-84% -$6.27M 0.01% 1134
2014
Q4 		$6.3M Buy
121,650
+1,397
+1% +$61.5K 0.04% 427
2014
Q3 		$5.29M Buy
120,253
+102,746
+587% +$3.21M 0.04% 473
2014
Q2 		$458K Buy
17,507
+6,502
+59% +$139K ﹤0.01% 1896
2014
Q1 		$288K Hold
11,005
– – ﹤0.01% 2210
2013
Q4 		$187K Hold
11,005
– – ﹤0.01% 2517
2013
Q3 		$236K Buy
+11,005
New +$191K ﹤0.01% 2291

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PTCT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of PTC Therapeutics (PTCT) in Q2 2024, closing a stake of 3,793 shares — an estimated $110K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PTCT in Q3 2013 and held it in 43 quarters. The position peaked at $6.3M in Q4 2014. 199 funds tracked by Wall St. Rank hold PTCT as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining PTC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,793 PTC Therapeutics shares in Q2 2024, an estimated $110K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in PTC Therapeutics in Q3 2013 and held it in 43 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s PTC Therapeutics position peaked at $6.3M in Q4 2014.
  • 199 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.